DexCom treats about 2.5 million patients, with tons of room for more. The company's Q2 guidance bombshell tanked the stock. Competition from an unexpected source raises long-term concerns worth ...
DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...
DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...
Dexcom shares sank more than 40% on Friday, their steepest decline ever. The company reported disappointing revenue on Thursday and lowered its full-year guidance. Executives blamed a restructuring of ...
Die DexCom Inc. (NASDAQ:DXCM) hat am 30. April die Ergebnisse für das erste Quartal 2026 vorgelegt, die die Erwartungen der Analysten übertrafen. Der führende Anbieter von Systemen zur kontinuierliche ...
DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
DexCom is one of the leaders in an industry with massive growth potential. The company is building a competitive advantage. Despite several risks, it could deliver substantial returns in the long run.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results